Aberdeen Group plc Trims Stock Position in Abivax SA Sponsored ADR $ABVX

Aberdeen Group plc lessened its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 45.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 426,658 shares of the company’s stock after selling 360,759 shares during the quarter. Aberdeen Group plc owned about 0.55% of Abivax worth $57,537,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. UBS Group AG boosted its holdings in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. purchased a new position in shares of Abivax during the 3rd quarter worth approximately $263,698,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Abivax in the 3rd quarter valued at approximately $132,800,000. TCG Crossover Management LLC lifted its holdings in shares of Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after buying an additional 1,055,000 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in shares of Abivax in the third quarter valued at approximately $84,900,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Stock Performance

ABVX opened at $118.37 on Friday. Abivax SA Sponsored ADR has a 1 year low of $4.77 and a 1 year high of $148.83. The company’s 50 day simple moving average is $117.64 and its 200 day simple moving average is $111.92. The stock has a market capitalization of $9.37 billion, a PE ratio of -22.04 and a beta of 1.68.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million for the quarter. As a group, sell-side analysts expect that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Barclays upped their price objective on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Oppenheimer set a $131.00 price target on shares of Abivax in a research note on Thursday, January 8th. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. Finally, Piper Sandler reissued an “overweight” rating and set a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $137.15.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.